Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.38 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568021 | 0.85 | CYP1A2 (0.43) | PTGDR2BRD4RXFP1BRD9 | |
| SCHEMBL4568016 | 0.83 | IDO1 (0.44) | GAA | |
| SCHEMBL4568020 | 0.83 | PPARG (0.40) | PPARGPPARAMAPK14BRD4CNR2 | |
| SCHEMBL4568014 | 0.82 | SMN1; SMN2 (0.41) | GAA | |
| SCHEMBL4568009 | 0.80 | NLRP3 (0.46) | CYP17A1KCNQ4KCNQ5PPARGMAPK14 | |
| SCHEMBL12044500 | 0.75 | HTT (0.47) | KCNQ4KCNQ5GAAMTNR1AMTNR1B | |
| SCHEMBL2773049 | 0.75 | ATR (0.46) | CYP17A1KCNQ4KCNQ5MAPK14RXFP1 | |
| SCHEMBL11658497 | 0.74 | HPGD (0.47) | GAA | |
| SCHEMBL24498563 | 0.74 | AAK1 (0.48) | CNR2 | |
| SCHEMBL4568373 | 0.74 | KMT2A (0.44) | PPARGPPARAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | CYP17A1 1315/4885KCNQ4 1730/4885KCNQ5 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.